Clinical Trial: Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma

U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07767630) titled 'Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma' on Aug. 12.

Brief Summary: Fractionated dosing of [211At]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma

Study Start Date: July 21

Study Type: INTERVENTIONAL

Condition: Neuroblastoma (NB)

Intervention: DRUG: [211At]MABG

Fractionated Dose

Recruitment Status: RECRUITING

Sponsor: Sichuan University

Information provided by (Responsible Party): Rong Tian, Sichuan University

Disclaimer: Curated by HT Syndication....